search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Match study


- candidate number2954
- NTR NumberNTR1164
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR18-dec-2007
- Secondary IDsSanquin: PPOC 06-017 CME-ZWH: 07-099 ABR: 17890  Sanquin, CME-ZWH, CCMO
- Public TitleMatch study
- Scientific TitlePreventive extended red blood cell matching: when and how?
- ACRONYMMatch study
- hypothesisInvestigate the benefits and costs of extended RBC antigen matching to prevent alloimmunization.
- Healt Condition(s) or Problem(s) studiedRed blood cell antibodies
- Inclusion criteriaThe general transfusion population >18 years requiring an elective RBC transfusion.
- Exclusion criteria1. Patients younger than 18 years;
2. Patients with an a priori indication for matched transfusions;
3. Patients with a positive direct antiglobulin test;
4. Patients who, based on the local pre-operative blood-ordering list, require more than 4 units during surgery;
5. Incapacitated subjects or patients who cannot understand the information.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2008
- planned closingdate1-aug-2010
- Target number of participants1120
- InterventionsPatients are randomly assigned to receive standard ABO-D matched or extended (C, E, c, e, K, Fya, Jka and S) matched RBC transfusions.
- Primary outcomeIncidence of alloimmunization in transfusion patients through preventive donor matching for the clinically relevant blood cell antigens compared to standard matching in patients stratified for high risk and random risk for alloimmunization.
- Secondary outcomeCost-analysis for current serologic screen and match strategy compared to preventive matching strategy in the two strata of patients.
Health benefits: investigate transfusion and/or other medical treatment delay in case of RBC alloimmunization. Clinical and genetic factors associated with alloimmunization.
- TimepointsFollow-up after 7-10 days, 1 month and 4-6 months following transfusion.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES H. Schonewille
- CONTACT for SCIENTIFIC QUERIES A. Brand
- Sponsor/Initiator Sanquin Blood Bank South West Region
- Funding
(Source(s) of Monetary or Material Support)
Sanquin Southwest
- PublicationsTo be expected.
- Brief summaryRationale:
Preventive extended matching for red blood cell (RBC) transfusions is currently only applied for high risk hematological patients and females of (pre) child-bearing age. RBC transfusions elicit antibodies in 2-9% after a first transfusion episode, but antibody responders have a high (>20%) risk for additional antibody formation upon subsequent transfusions. Prior to availability of new technology enabling large scale extended donor RBC antigen genotyping we propose to evaluate for which patients extensive matching is efficient and may be cost-effective.


Objective:
This study investigates the benefits and costs of extended RBC antigen matching to prevent alloimmunization. Preventive RBC matching will be evaluated in two transfusion populations with different (high and random) risks for alloimmunization. This will identify the population for which preventive matching will be most efficient as compared to a random population and reveal the optimal and cheapest application for an expected new intervention such as large scale genotyping of donors.


Study design:
Randomized controlled double-blinded multicenter intervention study.
Study population:
Patients with a first or subsequent transfusion event, stratified for patients with alloantibodies after a previous transfusion.


Intervention:
Patients are randomly assigned to receive standard ABO-D matched or extended (C, E, c, e, K, Fya, Jka and S) matched RBC transfusions.


Main study parameters/endpoints:
1. Decrease in alloimmunization in transfusion patients through preventive donor matching for the clinically relevant blood cell antigens (C, E, c, e, K, Fya, Jka and S), responsible for more than 80% of immunization cases, in patients stratified for high and random alloimmunization risk;
2. Cost-analysis for current serologic screen and match strategy compared to preventive matching strategy in the 2 strata of patients.
- Main changes (audit trail)
- RECORD18-dec-2007 - 9-apr-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl